Laboratory Adverse Events According to CTCAE, Version 4.03
| Adverse event | Grade 1 | Grade 2 | Grade 3 |
|---|---|---|---|
| AST increased | 22/31 (71%) | 2/31 (6%) | 5/31 (16%) |
| Platelet count decreased | 22/31 (71%) | 1/31 (3%) | |
| INR increased | 22/31 (71%) | 2/31 (6%) | |
| AP increased | 19/31 (61%) | 5/31 (16%) | |
| Anemia | 16/31 (52%) | 5/31 (16%) | 2/31 (6%) |
| ALT increased | 15/31 (48%) | 2/31 (6%) | |
| Hypoalbuminemia | 14/31 (45%) | 5/31 (16%) | 1/31 (3%) |
| Prolonged APTT | 13/31 (42%) | 2/31 (6%) | |
| Hyponatremia | 12/31 (39%) | 3/31 (10%) | |
| Hypokalemia | 9/31 (29%) | ||
| Hyperglycemia | 9/31 (29%) | 13/31 (42%) | 6/31 (19%) |
| Creatinine increased | 7/31 (23%) | 1/31 (3%) | |
| Bilirubin increased | 6/31 (19%) | 4/31 (13%) | 1/31 (3%) |
| GGT increased | 5/31 (16%) | 9/31 (29%) | 14/31 (45%) |
| Hypoglycemia | 3/31 (10%) | ||
| Lymphopenia | 1/31 (3%) | 13/31 (42%) | 9/31 (29%) |
AST = aspartate transaminase; INR = international normalized ratio; AP = alkaline phosphatase; ALT = alanine transaminase; APTT = activated prothrombin time; GGT = γ-glutamyltransferase.
This table represents new and highest toxicity during 6-mo follow-up. No laboratory adverse events grade 4 or 5 were observed.